Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection

Table 3 Adjustment of immunosuppression regimen in patients after renal transplantation treated with sofosbuvir and daclatasvir

	KT patient 1	KT patient 2	KT patient 3	KT patient 4	KT patient 5	KT patient 6
Baseline immunosuppressive regimen	Prednisone 5 mg qd	Prednisone 5 mg qd	Prednisone 5 mg qd	Methylprednisolone 4 mg qd	Prednisone 5 mg qd	Methylprednisolone 4 mg qd
	Mycophenolate mofetil 1.5 g bid	Mycophenolate mofetil 540 mg bid	Mycophenolate mofetil 540 mg bid	Mycophenolate mofetil 750 mg bid	Mycophenolate mofetil 540 mg bid	Mycophenolate mofetil 720 mg bid
	Tacrolimus (FK506) 0.5 mg bid	Tacrolimus (FK506) 1.5 mg bid	Tacrolimus (FK506) 2 mg bid	Tacrolimus (FK506) 2 mg bid	Cyclosporine 75 mg bid	Tacrolimus (FK506) 0.5 mg bid
1st adjustment	FK506 0.5 mg qd + 1 mg qn (3 wk after the treatment for his blood drug concentration of FK506 was 3.7 ng/mL).	No	No	Mycophenolate mofetil 1000 mg bid	Cyclosporine 75 mg qd + 50 mg qn (5 d after the treatment for his blood drug concentration of cyclosporine rose to 277.9 ng/mL).	No
				FK506 3 mg bid (11 wk after the treatment for his blood drug concentration of FK506 was 5.4 ng/mL).
2nd adjustment	FK506 4 mg bid (8 wk after the treatment for his blood drug concentration of FK506 was 6.4 ng/mL).	No	No	No	Mycophenolate mofetil 720 mg bid (45 d after the treatment was begun).	No
3rd adjustment	Mycophenolate mofetil 1000 mg bid (one month after the treatment)	No	No	No	No	No